1. Home
  2. BNTC vs ALT Comparison

BNTC vs ALT Comparison

Compare BNTC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • ALT
  • Stock Information
  • Founded
  • BNTC 1995
  • ALT 1997
  • Country
  • BNTC United States
  • ALT United States
  • Employees
  • BNTC N/A
  • ALT N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNTC Health Care
  • ALT Health Care
  • Exchange
  • BNTC Nasdaq
  • ALT Nasdaq
  • Market Cap
  • BNTC 335.5M
  • ALT 292.0M
  • IPO Year
  • BNTC N/A
  • ALT N/A
  • Fundamental
  • Price
  • BNTC $13.24
  • ALT $3.83
  • Analyst Decision
  • BNTC Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • BNTC 5
  • ALT 6
  • Target Price
  • BNTC $26.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • BNTC 39.5K
  • ALT 3.0M
  • Earning Date
  • BNTC 09-25-2025
  • ALT 08-12-2025
  • Dividend Yield
  • BNTC N/A
  • ALT N/A
  • EPS Growth
  • BNTC N/A
  • ALT N/A
  • EPS
  • BNTC N/A
  • ALT N/A
  • Revenue
  • BNTC N/A
  • ALT $20,000.00
  • Revenue This Year
  • BNTC N/A
  • ALT N/A
  • Revenue Next Year
  • BNTC N/A
  • ALT $761,880.20
  • P/E Ratio
  • BNTC N/A
  • ALT N/A
  • Revenue Growth
  • BNTC N/A
  • ALT N/A
  • 52 Week Low
  • BNTC $8.06
  • ALT $2.90
  • 52 Week High
  • BNTC $17.15
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 59.72
  • ALT 51.79
  • Support Level
  • BNTC $12.57
  • ALT $3.35
  • Resistance Level
  • BNTC $13.33
  • ALT $3.66
  • Average True Range (ATR)
  • BNTC 0.60
  • ALT 0.19
  • MACD
  • BNTC 0.10
  • ALT 0.07
  • Stochastic Oscillator
  • BNTC 95.59
  • ALT 86.18

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: